Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.9252W HIGH $6.42
Volume
478.88 K
Value Traded
5.74 M
Short % Float
32.02%
Days to Cover
8.7
+5.9%Week
-29.18%1 Month
-41.38%3 Month
-49.44%6 Month
-74.44%5 Year
-98.56%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
232.70 M
EPS (TTM)
-1.66
P/E Ratio
-
Ent. Value
76.95 M
Total Shares
103.85 M
Float Shares
48.00 M
Insiders
54.01%
Institutions
49.70%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
LRMR Catalyst Timeline
Dated clinical, regulatory and corporate events for Larimar Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Larimar Therapeutics, Inc.
478Total events
10Upcoming
100Tier-1 (high impact)
2014 to 2041Coverage
Upcoming catalysts 2
Event history 50
●Timing GuidanceNomlabofuspFiledPresentation
Submission of final modules for rolling BLA expected
Friedreich's Ataxiasource ↗
▲Trial InitiationNomlabofuspFiledTrial
First patient dosing in global confirmatory Phase 3 study expected Q3 2026
Friedreich's ataxiasource ↗
▲Enrollment UpdateNomlabofuspFiledTrial
Additional participants dosed in July; several adults and adolescents in screening
Friedreich's ataxiasource ↗
◆R&D DayNomlabofuspFiledPresentation
Investor event to discuss nomlabofusp program updates including regulatory update and data from ongoing long-term open label study
Friedreich's ataxiasource ↗
▲FDA Feedback ReceivedNomlabofuspFiledFDA Meeting
FDA alignment on BLA data package for accelerated approval
Friedreich's Ataxiasource ↗
●BLA SubmissionNomlabofuspFiledRegulatory Filing
First module of rolling BLA submitted to FDA
Friedreich's Ataxiasource ↗
▲Full ResultsNomlabofuspFiledClinical Data
Positive open label data: skin FXN levels, clinical outcomes
Friedreich's Ataxiasource ↗
●Oral PresentationNomlabofuspFiledPresentation
Company management webcast and conference call
Friedreich's Ataxiasource ↗
●Timing GuidanceNomlabofuspFiledPresentation
BLA submission planned for June 2026
Friedreich's ataxiasource ↗
▲First Patient DosedNomlabofuspFiledTrial
Plan to dose first patient in global confirmatory Phase 3 study in mid-2026
Friedreich's ataxiasource ↗
▲Full ResultsNomlabofuspFiledClinical Data
Longer-term open-label data showed sustained frataxin increases and clinical improvements
Friedreich's ataxiasource ↗
▲Pre BLA MeetingNomlabofuspFiledFDA Meeting
FDA agreed on key elements for BLA submission including FXN as surrogate
Friedreich's ataxiasource ↗
●Rolling Submission InitiatedNomlabofuspFiledRegulatory Filing
First module of rolling BLA submitted
Friedreich's ataxiasource ↗
▼Safety Data UpdateNomlabofuspFiledClinical Data
Long-term safety profile: anaphylaxis in 10 participants, all resolved
Friedreich's ataxiasource ↗
▲PublicationNomlabofuspFiledPresentation
Publication of cross-species findings supporting skin as surrogate for frataxin measurement
Friedreich's ataxiasource ↗
●Timing GuidanceNomlabofuspFiledPresentation
BLA submission for nomlabofusp seeking accelerated approval
Friedreich's Ataxiasource ↗
◆Topline ReadoutNomlabofuspFiledClinical Data
Topline OL study data to support BLA submission expected in Q2 2026
Friedreich's ataxiasource ↗
◆Trial InitiationNomlabofuspFiledTrial
Global Phase 3 confirmatory study expected to be underway at time of BLA submission
Friedreich's ataxiasource ↗
▲PublicationNomlabofuspFiledPresentation
Cross-species nonclinical findings on skin FXN levels published in Clinical and Translational Science
Friedreich's ataxiasource ↗
◆Type B MeetingNomlabofuspFiledFDA Meeting
Type B meeting with FDA scheduled later in Q2 2026 to align on BLA data package readiness
Friedreich's ataxiasource ↗
◆Oral PresentationPresentation
Larimar management to present at Citizens Life Sciences Conference
◆Oral PresentationPresentation
Larimar management to present at Leerink Partners Global Healthcare Conference
▼Equity OfferingCorporate
Pricing of upsized $100 million underwritten public offering of 20,000,000 shares at $5.00 per share
▲Breakthrough Therapy DesignationNomlabofuspFiledDesignation
FDA granted Breakthrough Therapy Designation for nomlabofusp in FA
Friedreich's ataxiasource ↗
▲FDA Feedback ReceivedNomlabofuspFiledFDA Meeting
FDA feedback from START meeting supporting BLA content and surrogate endpoint
Friedreich's ataxiasource ↗
▲Breakthrough Therapy DesignationNomlabofuspFiledDesignation
FDA granted Breakthrough Therapy Designation to nomlabofusp for FA
Friedreich's ataxiasource ↗
▲FDA Feedback ReceivedNomlabofuspFiledFDA Meeting
FDA meeting comments support continued alignment for BLA submission
Friedreich's ataxiasource ↗
◆Timing GuidanceNomlabofuspFiledPresentation
Nomlabofusp development program update including regulatory discussions and OL study status in Q1 2026
Friedreich's ataxiasource ↗
◆Timing GuidanceNomlabofuspFiledPresentation
BLA submission for nomlabofusp to support potential accelerated approval
Friedreich's ataxiasource ↗
◆Oral PresentationNomlabofuspFiledPresentation
Conference call to discuss nomlabofusp clinical development program including data from ongoing long-term open label study
Friedreich's ataxiasource ↗
▲Full ResultsNomlabofuspFiledClinical Data
Positive 25 mg and 50 mg data from ongoing long-term open label study
Friedreich's ataxiasource ↗
●Protocol AmendmentNomlabofuspFiledTrial
Protocol amended to include adolescent and adult patients not previously in nomlabofusp studies
Friedreich's ataxiasource ↗
●Timing GuidanceNomlabofuspFiledPresentation
Key upcoming milestones for nomlabofusp program
Friedreich's ataxiasource ↗
▲Oral PresentationNomlabofuspFiledPresentation
Long-term data from OL study presented showing 100% of participants achieved skin FXN levels over 50% of median healthy volunteers at 6 months
Friedreich's ataxiasource ↗
▲Full ResultsNomlabofuspFiledClinical Data
Long-term data from OL study: 2.25 median improvement in mFARS at 1 year vs worsening in FACOMS reference population
Friedreich's ataxiasource ↗
◆Topline ReadoutNomlabofuspFiledClinical Data
Data report including 50 mg dose from OLE study and adolescent PK run-in data
Friedreich's Ataxiasource ↗
●Enrollment UpdateNomlabofuspFiledTrial
39 participants dosed, 25 receiving daily dosing as of August 27, 2025
Friedreich's ataxiasource ↗
▼Equity OfferingCorporate
Closing of underwritten public offering of 21,562,500 shares at $3.20 per share, including full exercise of underwriters' option
▼Equity OfferingCorporate
Pricing of underwritten public offering of 18,750,000 shares at $3.20 per share for gross proceeds of $60.0 million
▲PublicationNomlabofuspFiledPresentation
Publication of two peer-reviewed articles on nonclinical data for nomlabofusp
Friedreich's ataxiasource ↗
▼Equity OfferingCorporate
July 2025 common stock public offering raised $65.0 million net proceeds
Past FDA Catalysts and PDUFA Decisions
How LRMR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2021-06-30 | CTI-1601 | Phase 1 topline data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 58%
Micro Cap(rank 381 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nomlabofusp Monoclonal antibodyNCT04519567 | Friedreich Ataxia | Phase 3 | COMPLETED | 318 | Mar 16, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every LRMR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| nomlabofusp BreakthroughFast TrackOrphan+1 | Friedreich's ataxia | 2025-09-29 | consistent improvements in clinical outcomes; increased frataxin levels; 25 mg and 50 mg data; achieving tissue FXN levels equivalent to more than 50% of those found in healthy volunteersRead More | Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s AtaxiaRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Hamilton Thomas EdwardDirector | Buy | 50,000 714,798 held | $3.34 | 07/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LRMR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 0.1 % | 7.83 M | 2.57 M | 71.07% ( 1.07 M) |
LRMR Institutional Ownership Trends
LRMR Short Interest
Shares sold short, counted twice a month.
32.02%
Short % of Float
of tradable shares sold short
15.4M
Shares Sold Short
+10.6% vs prior count
8.7 High
Days to Cover
trading days of normal volume to buy every short share back
1.8M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LRMR ranks across every disease it competes in
Competitive Position is a premium feature
See how LRMR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLRMR News
LRMRLarimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer
Larimar Therapeutics has appointed John Harlow as President and Chief Operating Officer, effective September 29, 2026. Harlow, with over 25 years of experience in the biopharmaceutical industry, is expected to play a crucial role in advancing the company's lead compound, nomlabofusp, towards potential approval. His previous roles include Chief Commercial Officer at Esperion Therapeutics and Melinta Therapeutics.
Read more →LRMRLarimar Therapeutics Reports Second Quarter 2026 Financial and Business Update
Larimar Therapeutics reported positive data from its open label study of nomlabofusp, showing a well-characterized safety profile and sustained improvements in clinical outcomes for Friedreich's ataxia. The company has initiated a rolling BLA submission for accelerated approval and expects to begin dosing in a global Phase 3 study in Q3 2026. Financially, Larimar holds $156.3 million in cash, projecting a runway into Q3 2027.
Read more →LRMR▼ -12.6%on this news
Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia
Larimar Therapeutics has submitted the first module of its rolling Biologics License Application (BLA) for nomlabofusp, aimed at treating Friedreich's ataxia. Positive results from a long-term open label study showed significant improvements in skin FXN levels and clinical outcomes. The FDA has indicated that the existing data supports the BLA submission, with further modules expected by the end of 2026.
Read more →LRMR▼ -12.6%on this newsshared move
Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia
Larimar Therapeutics announced an investor event scheduled for June 29, 2026, to discuss updates on its nomlabofusp program for Friedreich's ataxia. The event will include a regulatory update and data from ongoing studies. Larimar aims to develop treatments for complex rare diseases, with nomlabofusp as a key candidate.
Read more →LRMR▼ -5.1%on this news· ran to -19% by day 3
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update
Larimar Therapeutics reported its Q1 2026 financial results, highlighting plans for a rolling BLA submission for nomlabofusp, aimed at treating Friedreich's ataxia. The company has received Breakthrough Therapy Designation from the FDA and expects to report topline data from an open-label study in Q2 2026. With $200.4 million in cash, Larimar is positioned to advance its clinical programs.
Read more →LRMR▼ -6.5%on this news
Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia
Larimar Therapeutics has published findings supporting the use of skin as a surrogate for measuring frataxin levels in patients with Friedreich's ataxia. The study indicates that treatment with nomlabofusp increases frataxin levels in peripheral tissues, correlating with levels in critical organs. These findings bolster Larimar's plans for accelerated approval from the FDA and a Biologics License Application submission scheduled for June 2026.
Read more →LRMRLarimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Larimar Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting the receipt of Breakthrough Therapy Designation from the FDA for nomlabofusp, aimed at treating Friedreich's ataxia. The company successfully raised $115 million in a public offering, extending its cash runway into the second quarter of 2027. Plans are in place to initiate a global Phase 3 confirmatory study in mid-2026 and submit a Biologics License Application seeking accelerated approval in June 2026. However, the company reported a net loss for 2025 of $165.7 million, reflecting significant increases in research and development costs.
Read more →LRMR▲ +9%on this news
pro March 2026 Larimar Therapeutics Corporate Deck Forward-Looking Statements This presentation contains forward-looking statements that are based on Larimar's management's beliefs and assumptions and on information curr
Larimar Therapeutics has shared an update on its promising drug candidate nomlabofusp, which has received FDA Breakthrough Therapy Designation for Friedreich's Ataxia (FA). The company plans to submit a Biologics License Application (BLA) in June 2026, following positive early clinical results that show significant improvements in FXN levels. However, various risks remain, including potential delays and uncertainties in clinical trial outcomes.
Read more →LRMRLarimar Therapeutics to Participate in Upcoming Investor Conferences in March 2026
Larimar Therapeutics, a clinical-stage biotechnology company, announced its participation in two upcoming investor conferences in March 2026. The conferences will take place in Miami Beach, FL, where the management team will present and hold 1x1 meetings with investors. The company aims to showcase its lead compound, nomlabofusp, which targets Friedreich's ataxia.
Read more →LRMR▼ -7.2%on this news
Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering
Larimar Therapeutics has announced a proposed underwritten public offering of $75 million in common stock and pre-funded warrants. The company plans to utilize the proceeds for the development of its lead compound, nomlabofusp, and for general corporate purposes. The offering is contingent on market conditions and may not be finalized as planned.
Read more →LRMR▼ -7.2%on this news
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering
Larimar Therapeutics has announced the pricing of its upsized public offering, raising $100 million by selling 20 million shares at $5.00 each. The offering is set to close around February 27, 2026, and the proceeds will be used for the development of nomlabofusp and general corporate purposes. The company has granted underwriters a 30-day option for additional shares.
Read more →LRMR▲ +31.3%on this news· ran to +112% by day 1shared move
Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026
Larimar Therapeutics has received Breakthrough Therapy Designation from the FDA for nomlabofusp, a treatment for Friedreich's ataxia. The designation highlights the drug's potential to significantly improve clinical outcomes based on preliminary data. The company plans to submit a Biologics License Application (BLA) by June 2026, aiming for accelerated approval. FDA feedback indicates alignment on clinical endpoints and study design.
Read more →LRMRpro January 2026 Larimar Therapeutics Corporate Deck Forward-Looking Statements This presentation contains forward-looking statements that are based on Larimar's management's beliefs and assumptions and on information cu
Larimar Therapeutics presented its corporate deck highlighting forward-looking statements regarding the development of nomlabofusp, a potential treatment for Friedreich's ataxia. The company aims to register this first-in-class mitochondrial protein replacement therapy, targeting systemic frataxin deficiency. Strong preliminary studies support the efficacy of nomlabofusp, and regulatory pathways appear promising. However, the management acknowledges risks and uncertainties associated with the drug's development timeline and regulatory approvals.
Read more →LRMRLarimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Larimar Therapeutics, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, in San Francisco. The presentation by the management team will take place on January 14 from 9:00 to 9:40 AM PST, followed by a 30-day replay available on their website. The company is focused on developing treatments for complex rare diseases, particularly its lead compound for Friedreich's ataxia.
Read more →LRMRpro November 2025 Larimar Therapeutics Corporate Deck Forward-Looking Statements This presentation contains forward-looking statements that are based on Larimar's management's beliefs and assumptions and on information c
Larimar Therapeutics has presented forward-looking statements regarding its drug nomlabofusp for Friedreich's Ataxia (FA), suggesting strong potential as a disease-modifying therapy. Initial open-label studies indicated significant increases in skin frataxin levels and improvements across clinical metrics in study participants. While results are promising, there are concerns about adverse events such as anaphylaxis and uncertainty in FDA interactions affecting future developments. Larimar targets a Biologics License Application submission by Q2 2026, contingent on continued positive results and further clinical data.
Read more →LRMR▼ -15.3%on this newsshared move
Larimar Therapeutics Reports Third Quarter 2025 Financial Results
Larimar Therapeutics reported a third quarter net loss of $47.7 million, or $0.61 per share. The company holds $175.4 million in cash and projects a runway through the fourth quarter of 2026. Nomlabofusp showed consistent improvement in clinical measures for Friedreich’s ataxia patients. Larimar aims to submit a Biologics License Application for accelerated approval in the second quarter of 2026.
Read more →LRMRpro October 2025 Larimar Therapeutics Corporate Deck Forward-Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. ( “
Larimar Therapeutics has provided an update on its development of nomlabofusp, with initial results indicating its potential as a disease-modifying therapy for Friedreich's Ataxia (FA). A corporate deck presented forward-looking statements regarding the drug's regulatory path, including plans for a Biologics License Application (BLA) in Q2 2026. Despite encouraging data showing significant improvements in skin FXN levels among trial participants, the company faced challenges, including adverse events like anaphylaxis, which led to modifications of the clinical regimen. Overall, Larimar remains optimistic about nomlabofusp's potential and its alignment with FDA guidelines for accelerated approval.
Read more →LRMR▼ -33.7%on this newsshared move
Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia
Larimar Therapeutics reported positive data from its ongoing open-label study of nomlabofusp for Friedreich’s ataxia. Ten out of ten participants achieved skin frataxin levels above 50 percent of healthy volunteer medians after six months. The company also announced a modified starting dose regimen following seven anaphylaxis cases. Larimar plans to submit a biologic license application in the second quarter of 2026.
Read more →LRMR▼ -33.7%on this newsshared move
Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia
Larimar Therapeutics has announced a conference call scheduled for September 29, 2025, to discuss updates on its nomlabofusp clinical development program for Friedreich's ataxia. The call will include data from an ongoing long-term open label study. Participants can join via phone or webcast, with an archived version available post-event.
Read more →LRMR▲ +14.5%on this news
Larimar Therapeutics Reports Second Quarter 2025 Financial Results
Larimar Therapeutics reported its financial results for the second quarter of 2025, highlighting a net loss of $26.2 million. The company continues to advance its nomlabofusp program with initial data from the 50 mg open label study and adolescent PK run-in expected in September 2025. Additionally, plans to submit a Biologics License Application seeking accelerated approval in Q2 2026 are underway. The company also announced a strengthened balance sheet following a public offering that extended its cash runway into late 2026.
Read more →About Larimar Therapeutics, Inc.
HeadquartersTHREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA, 19004
BIOPHARMAWATCH ELITE PLUS
Trade the next LRMR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime